Evidence Based Data

Dendritic Cell Therapy

What is Dendritic Cell Therapy?

 

Dendritic cell therapy is a type of immunotherapy that is used to treat cancer. It is also known as the Dendritic cells vaccine.

dendritic cell

Dendritic Cell vaccine is completely customized to each person

 

How Is the Dendritic Cell Vaccine Made?

 

The most unique attribute of Dendritic cell therapy is that it is completely customized to each person and their individual cancer.

In order to create this vaccine, a blood sample is drawn from the patient. The sample is sent to the lab where it is studied and processed in order to create individualized treatments that will operate against the cancerous cells.

Some clinics such as Sanoviv perform a full autologous process, in which a biopsy sample is also taken directly from the patient’s tumor.

In these cases, when a biopsy sample is taken, at the same time, an additional blood sample is drawn as well. Both samples are then taken to a lab where they are studied and cultured in order to make a vaccine that will operate against the cells that constitute the patient’s cancer.

Each vaccine is completely unique and literally, one of a kind.

 

 

autologous-dendritic-vaccine

A biopsy sample is taken directly from the patient’s tumor

 

What is the Mechanism of Dendritic Cell Therapy?

 

In the lab, specialists locate specific cells in the patient’s blood that can be used to generate the vaccine.
These cells are called macrophages. A macrophage is a type of immune cell that is made in the bone marrow.
These cells are “trained” in the lab to become the strongest possible “fighter cells.” Part of this process involves testing them, changing their microenvironment, and putting them in contact with growth factors.
After all of this, the cells are then put in contact with stimuli that generate an immune response, and are bathed with an inflammatory microenvironment that activates them.
Once activated, the primed immune cells are introduced to the tumor cells in the lab.
Dendritic cells possess the ability to activate specific “memory” cells that recognize antigens in the tumor, these antigens have to be previously “presented” to them, by the dendritic cells.
With this information, dendritic cells then instruct the body to fight against certain kinds of antigens and recognize specific markers of the cancer. By doing this, they are able to turn on the body’s immune response against the patient’s exact type of cancer.

 

dendritic cell vaccine

Dendritic cells turn on the body’s immune response against the patient’s exact cancer


How Does a Patient Receive the Dendritic Cell Vaccine?

 

The process described above takes roughly about a week. Upon its completion, the vaccine is then injected into the patient, usually as close as possible to the tumor site, near lymphatic nodes.

The patient generally receives between 4-6 vaccine shots per sample, usually on a weekly basis, though some doctors may recommend twice a week for some patients.

According to Isaac Meza, M.D., and Jose Luis Flores, Ph.D. Molecular Biomedicine, Sanoviv’s Medical Director and Head Research Scientist respectively, it is of the utmost importance for a patient to undergo integrative treatment while receiving dendritic cell therapy.

 

Isaa-Meza

“DC therapy is best integrated with other therapies” Dr. Meza


Factors such as detoxification, a patient’s environment, nutrition and psychological state all weigh in heavily on any type of immunotherapy for cancer. It is highly recommended to integrate the vaccine as part of a full program that addresses all aspects of healing. Most clinics do not offer dendritic cell therapy on its own.


What Are the Side Effects of Dendritic Cell Therapy?

 

Possible side effects can include chills or a mild fever after receiving the vaccine.


T
he History of Dendritic Cell Therapy

 

Dr. William Coley is attributed with recognizing the interaction between cancer cells and the immune system in the 1890s. He went on to treat his patients with a form of a therapy called Coley’s Toxins which led to the development of Dendritic cell therapy vaccines today. The first clinical trial of dendritic cell therapy was launched in 1996 and the first dendritic cell vaccine was approved by the FDA in 2010 under the name Sipuleucel-T (Provenge).

Special thanks to Sanoviv Medical Institute, Isaac Meza, M.D., Sanoviv Medical Director, and Jose Luis Flores, Ph.D., Molecular Biomedicine, Sanoviv Head Research Scientist for their breakdown of Dendritic Cell Therapy.

 

 

image clinic
photo
Oasis of Hope Hospital, Paseo Playas de Tijuana, Playas, Terrazas, Tijuana, Baja California, Mexico
4.4
image clinic
photo
Torre Norte 2, Fray Servando Teresa de Mier, Zona Río, Tijuana, Baja California, Mexico
image clinic
photo
Boulevard Luis Donaldo Coloso (Av Tulum) Manzana, Cancún, Mexico
5
image clinic
photo
C. Oaxtepec 12121, Hacienda Agua Caliente, Tijuana, Baja California, Mexico
5.0
image clinic
photo
Paseo de los Héroes 9211, Zona Río, Tijuana, Baja California, Mexico
4.7
image clinic
photo
4370 La Jolla Village Drive, San Diego, CA, USA
4.5
Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer
Steven’s Positive Outcome Against Cancer with Integrative Treatment at Verita Life
Dendritic Cell Therapy for Multiple Myeloma Patients

Dendritic Cell Therapy- Relevant Research and News

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

Dendritic cells (DCs) are the most potent antigen-presenting cells and are the key initiator of tumor-specific immune responses. These characteristics are exploited by DC therapy, where DCs are ex vivo loaded with tumor-associated antigens (TAAs) and used to induce tumor-specific immune responses. Unfortunately, clinical responses remain limited to a proportion of the patients. Tumor characteristics and the immunosuppressive tumor microenvironment (TME) of the tumor are likely hampering efficacy of DC therapy. Therefore, reducing the immunosuppressive TME by combining DC therapy with other treatments could be a promising strategy. Initially, conventional cancer therapies, such as chemotherapy and radiotherapy, were thought to specifically target cancerous cells. Recent insights indicate that these therapies additionally augment tumor immunity by targeting immunosuppressive cell subsets in the TME, inducing immunogenic cell death (ICD), or blocking inhibitory molecules. Therefore, combining DC therapy with registered therapies such as chemotherapy, radiotherapy, or checkpoint inhibitors could be a promising treatment strategy to improve the efficacy of DC therapy. In this review, we evaluate various clinical applicable combination strategies to improve the efficacy of DC therapy.

You might also be interested in

Mistletoe / Iscador / Helixor

Mistletoe Therapy

Click here to buy Iscador/ Mistletoe directly – Shipping worldwide>>   Mistletoe: Can it Help Treat Cancer? How Do I Take It?   Mistletoe is one of the most widely studied

Read More »
Colon Hydrotherapy

Colon Hydrotherapy

What is Colon Hydrotherapy?   Colonic hydrotherapy has been used for thousands of years and is still used in clinics worldwide. It’s a completely natural and risk-free remedy that has been

Read More »
gcmaf

GcMAF

GcMAF is a vitamin D-binding protein. The name GcMAF is short for Glycoprotein Macrophage Activating Factor and is what is scientifically referred to as a GC-protein. Let’s simplify: A GC-protein is

Read More »

Looking for clinics offering Dendritic Cell Therapy?

We can help!

Interested in Dendritic Cell Therapy but not sure how to start? We can help

We’ll connect you with a specialist within 24 hours

Looking for alternative cancer treatments?

Our advisors have helped hundreds of patients navigate their alternative options.

This website uses cookies to ensure you get the best experience.